Terminal maturation of resting B cells by proliferation-independent B cells differentiation factors by unknown




From the Division of Clinical Immunology, Mount Sinai Medical Center, New York 10029
The pathway of normal B cell activation is a network of complex regulatory
events (1-3). Although the goal of a directed immune response is to generate
antigen-specific antibodies, a large component of this response is actually poly-
clonal and nonspecific. Examples of this phenomenon are seen regularly with
antigen-specific immunization, as there is a concomitant rise in antibody titers
directed against noncrossreacting antigens (4). This nonspecificity appears to be
mediated, in large part, by soluble factors that stimulate either growth or
differentiation of local B cell clones (1-3, 5, 6). Current models of lymphokine
regulation of B cell maturation suggest that resting, Go B cells are preactivated
by antigen in vivo, or anti-IgM antibodies in vitro, to become responsive to B
cell-stimulatory factor (BSF-1, reference 1).' After exposure to growth factors,
B cells proliferate and generate receptors for factors regulating terminal matura-
tion, antibody production, and secretion (B cell differentiation factors [BCDF],
1-3). Recently, it has become evident that such a model is not sufficient to
explain the heterogeneity of B cell growth (7) and differentiation (8) factors.
Furthermore, weand others (8-10) have now described nonspecific proliferation-
inducing factors (B cell proliferation factor [BCPF] and BSF-1) that act on
resting, Go B cells without preactivation, a finding that suggests that, even at this
early stage, B cells have receptors for growth factors.
An analogous situation may hold true for differentiation factors. In fact, there
has been some evidence for the dichotomy of proliferation and differentiation.
Previous studies (11) using monoclonal leukemic B cell populations showed that
these cells could undergo terminal maturation without evidence of cell division.
Furthermore, induction of proliferation with anti-A or anti--y antibodies success-
fully blocked PWM-induced B cell maturation (12), although itis unclear whether
this was related to active proliferation or the presence of anti-Ig in culture. In
the murine system, B cell maturation factors (13-14) thatappear to act on resting
splenic B cells have been reported. In normal B cell preparations, we have
observed that actively proliferating B cells in culture do not undergo terminal
maturation 'consistently; rather, there appears to be an inverse correlation
between proliferation and differentiation. In this paper we extend these obser-
vations to show that active proliferation actually blocks B cell responses to B cell
'Abbreviations used in this paper:
￿
BCDF, B cell differentiation factor; BCGF, B cell growth factor;
BCPF, B cell proliferation factor; BSF-1, B cell-stimulatory factor 1, BCAF-1 ; CM, culture medium;
HU, hydroxyurea; SAC, Staphylococcus aureus Cowan I strain organisms; SPA, Staph protein A.
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differentiation signals and that terminal maturation to plasma cells can occur,
without any division, in resting B cells. These findings may help to explain much
of the nonspecificity inherent in the immune response and may serve to change
our conceptual model of normal B cell maturation .
Materials and Methods
Cell Separation and Culture Conditions.
￿
PBMC from normal controls were obtained
after Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) gradient centrifugation.
T/B cell separation was performed as previously described using neuraminidase treated
SRBC (15). All cultures were performed in RPMI 1640 (KC Biologic, Lenexa, KY), 1%
penicillin/streptomycin (Gibco Laboratories, Grand Island, NY), 2 mM glutamine (Gibco
Laboratories) and 10% FCS (Hazelton-Dutchland, Denver, PA), henceforth termed cul-
ture medium (CM) . In some experiments, formalin-fixed Staphylococcus aureus Cowan I




Human B cell differentiation factors MOW 10, MOPIL, and
MTP7 were derived from cloned T cell hybridomas from three different fusions (16).
These factors were devoid of any IL-2, IFN-y, B cell growth factor (BCGF), or BCPF
activity (16). BCDF-RAC was obtained as supernatant from an IL-2-dependent T cell
clone (9), 48-72 h after restimulation with IL-2 . BCPF was obtained from the T cell
hybrid MOW 1 (9, 16). Unless otherwise indicated, all supernatants were used from
standard stocks at 10% vol/vol.
Counterflow Elutriation.
￿
We performed elutriation with a JE-6 elutriator rotor (Beck-
man Instruments, Palo Alto, CA), using a modification of the method of Wahl et al. (17).
The chamber was equilibrated with PBS/I% BSA at a constant speed (2,000 rpm) at 18°C
in a J2-21 centrifuge (Beckman Instruments, Inc ., Palo Alto, CA). 1-3 x 108 non-T cells
were slowly injected into the chamber with an initial flow rate of 6 ml/min. Eight 150-ml
fractions were collected by stepwise increases in flow rate while maintaining a constant
rotor speed. Fractions were pelleted, washed in PBS, resuspended, and sized and plotted
by a Channelyzer (Coulter Electronics Inc., Hialeah, FL). A standard curve for cell size
was generated with calibrated beads.
Assay for B Cell Proliferation.
￿
Pansorbin (0.1-0.001% vol/vol) or BCPF (10-0 .01%)
was added to 106 non-T cells in CM on day 0. At 24, 48, 72, 96, and 110 h, triplicate
100-il aliquots were removed from these cultures and transferred to microwell cultures
with the addition of 2 uCi of [3H]methyl thymidine (Schwarz/Mann Div., Orangeberg,
NY; sp act, 1 .9 mCi). 18 h after the addition of the isotope, the wells were harvested and
counted, as previously described (16). Data for day 3, usually the highest response date,
are depicted in the results section. Hydroxyurea (HU) (Sigma Chemical Co.) was added




A reverse hemolytic plaque assay was performed on day
6, as previously described (16), using Staph protein A (SPA)-coated SRBC and goat anti-
human Ig as developing antiserum (Cappel Laboratories, Cochranville, PA).
Immunofluorescence Staining.
￿
Isolated fractions were stained with OK3, T4, T8, and
M1 from Ortho Diagnostic Systems Inc. (Raritan, NJ), VG 2 (framework anti-la mono-
clonal kindly provided by Dr. Shu Man Fu, Oklahoma Medical Research Foundation,
Oklahoma City, OK), goat anti-human Ig (Cappel Laboratories), EL2 (mAb analogous to
4F2/B cell activation marker) (18), anti-Tac (kindly provided by Dr. Thomas Waldmann,
National Cancer Institute, Bethesda, MD), and B 1 (Coulter Electronics Inc.). Staining and
analyses were performed as previously described (15).
Results
Proliferation Is a Negative Signalfor B Cell Differentiation.
￿
In contrast to some




Proliferation Negatively ImpactsB Cell Differentiation
*105 B cellscultured in triplicate in the presence of SAC or BCPF for 72 h. [3Hlmethyl thymidineis
added for the final 18 h of culture with results expressed as mean cpm of triplicate cultures. The
data presented are representative of at least five experiments.
$106 B cells arecultured for6 d in the presence ofone of four different BCDF preparations t SAC
or BCPF. A reverse plaque assay fortotal Ig is performed on day 6. The data are representative of
at least five experiments.
B cells undergoing active proliferation do not result in terminal maturation to
Ig-secreting cells. To address this observation more directly, we sought to
determine the effects of factors inducing proliferation on the B cell response to
BCDF(s). Either high-dose SAC (0.1-0 .01% vol/vol) or BCPF (10-1%) were
added on day 0 to cultures of isolated B cells with one of four different BCDF
preparations. As can be seen in Table I, in each case where active proliferation
is noted, the response to BCDF(s) was blunted or absent, compared with cultures
without any proliferation signal . This inhibition was reversed as the degree of
proliferation decreased, with lower concentrations of SAC or BCPF. This inhi-
bition of maturation was notdue to a change in the kinetics ofthe BCDF response
(Fig. 1), as no PFC response was demonstrable up to day 12 when BCPF was
added on day 0. Furthermore, even when BCDF was added from 24-96 h after
SAC or BCPF, no terminal differentiation was noted, suggesting that these
proliferative signals were not delaying expression of receptors for BCDF. Super-
natants of proliferating B cells (induced by SAC) did not, in themselves, induce
inhibition of BCDF response, showingthat proliferating B cells were notsecreting
any inhibitory factors (data not shown). In addition, the inhibition could not be
reversed by replacing cultures with fresh medium nor by changes in cell concen-
trations, suggesting that nutrient depletion and crowding did not appear to play
a role (data not shown).
Differentiation Occurs in the Absence of Proliferation.
￿
To further characterize
the role, if any, of proliferation in normal B cell maturation, we added varying
concentrations of HU (10-3-10-7 M) to cultures of B cells and any one of four
different BCDF preparations. These concentrations of HU were shown, in
separate experiments, to block both T and B cell responses to mitogens and
antigens (Table II and data not shown). As noted in Table II, HU appears to
inhibit the PFC response to the conventional B cell maturation signal, T cells




(cpm)* 0 MOW 10
PFC perwell*
MOPIL MTP7 RAC
0 225 90 3,120 6,480 1,920 2,150
0.1 33,126 0 10 40 90 70
0.01 21,465 10 40 40 120 30
0.001 9,123 10 2,520 3,680 920 2,260
BCPF(%)
10 7,125 80 110 20 180 150
1 4,122 80 140 690 210 600
0.1 578 60 4,230 3,240 1,560 1,910386 TERMINAL MATURATION OF RESTING B CELLS
FIGURE 1 .
￿
Kinetics ofBCDF response after the addition ofMOW 1/BCPF (10% vol/vol) to
106 B cells on day 0 . MOPIL/BCDF (10% vol/vol) is added to these cultures on either day 0
or after 24, 48, 72, or 96 h . A reverse hemolytic plaque assay is performed every day up to
day 12, as described in Materials and Methods . Response to MOPIL/BCDF alone is depicted
by the solid line graph(-).
TABLE II
Proliferation-dependent and -independent BCDFs
*Varying concentrations ofHU (10-s-10-7 M) are added to cultured B cells ± BCDF on day 0 . Dose
range waschosen for ability to inhibit both T (PHA) and B (SAC) cell mitogen responses ; at 10-s
M, 100% inhibition for T and B; 10-4 , 90% T/93% B; 10-5 , 91% T/95% B; 10-6 , 82% T/91% B;
10-', 61% T/53% B.
*As per Table I .
¢Viability and recovery of 106 B cells in culture on day 6 t HU as follows : no HU, 71% ; 10-s M,
23%; 10-4 M,48%;10-' M,76%; 10-6 M, 73%; 10-7 M, 70%.
and viability . In contrast, both MOPIL and MOW 10 induce PFC responses
comparable to control cultures in the presence of 10-5 and 10-6 M HU . At
higher concentrations (10-s and 10-4 M) both cell recovery and viability were
reduced, accounting for the marked inhibition of all responses (Table 11) ;
however, at lower concentrations (10-5-10-7 M) cell recovery and viability were
unaffected . Similar data were obtained using thymidine blockade (data not
shown) . These findings suggest that there may be two types of BCDF(s) : A
proliferation-dependent variety, analogous to the conventional T cell and PWM
signal ; and a proliferation-independent type that can induce terminal maturation







0 20 5,470 2,210 1,630 1,010 7,130
10-3M§ 0 0 10 0 0 0
10-'M 0 110 610 0 10 0
10-5 M 20 6,120 2,700 90 0 10
10 -1,M 90 9,390 2,560 1,200 630 3,170






































Fractions of non-T cells are collected by counterflow elutriation and analyzed
for size by a Channelyzer (Coulter Electronics, see Materials and Methods). Unseparated
mononuclear cells and isolated non-T cells are depicted for comparison. Cell size was
extrapolated from standardized calibrated beads (expressed as Am').
evidence for the heterogeneity of B cell differentiation factors, as previously
proposed (8, 9).
Proliferation-independent BCDFs Induce Terminal Maturation ofDense Resting B
Cells. An alternative explanation for the findings noted above is that both
MOPIL and MOW 10 are acting on B cells that have either already undergone
proliferation or have been activated in vivo. To isolate purer populations of
resting and activated cells, B cells were separated by counterflow elutriation. In
Fig. 2 profiles of unseparated non-T cells, as well as eight isolated fractions, are
depicted by size and cell volume (range, 140-215 um). The staining character-
istics of each fraction are noted in Table III. The early fractions (1-3) are
remarkable for the absence ofany activation marker (4F2, Tac). The 4F2+ cells
increase thereafter to a maximum in fraction 8 (macrophages). Tac was present
in fractions 5-7, with peak staining in fraction 6.
Each fraction was analyzed for response to three different B cell maturation
signals, MOW 10 (our proliferation-independent BCDF), SAC and IL-2, a more
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TABLE III
Staining Characteristics ofElutriated Non-T Cells
Aliquots of each elutriated fraction were stained with specific mAbs as





Response to BCDF/MOW 10 (-), IL-2 (----), or IL-2 and SAC 0.001%
(- ---) by elutriated fractions, measured on day 6 by a reverse hemolytic plaque assay .
Fraction 0 is nonelutriatednon-T cells showing baseline responses .
conventional pure B cell signal (19) and IL-2, recently shown to induce differ-
entiation of Tac+ B cells (20-23). Fig . 3 depicts a representative experiment .
The response to MOW 10 appears to reside in the early B cell fractions,
correspondingwith thedense resting Bcell . In contrast, IL-2 only affects terminal
maturation of Tac+-activated B cells, confirming data reported by others (24) .
The combined signal ofSAC and IL-2 is effective in virtually all fractions and is
probably related to the ability of SAC to induce Tac positivity on B cells (25) .
Thus it appears that MOW 10 is acting on dense resting 4F2- B cells, not in
vivo-activated cells, and suggests that even resting B cellshave a full complement
of receptors for both growth and differentiation factors .
Non-T Positive staining (%)
fraction sIg 4F2 TAC OKT3 OKM1
0* 24.6 49.6 1 .4 1 .3 53 .2
1 3.2 <0 .1 <0 .1 <0 .1 <0 .1
2 4.2 <0 .I <0 .1 <0 .5 <0 .1
3 14.6 <0 .1 <0 .1 0.8 <0 .1
4 31 .6 0.4 <0 .1 <0.5 <0 .1
5 27.6 3.2 0.5 <0.5 3 .7
6 37.9 6.7 31 .9 <0.5 3.1
7 19.6 21 .9 3.7 <0.5 16 .7




Some previous models of B cell maturation have suggested that B cell prolif-
eration is an integral and necessary prerequisite for terminal maturation and
antibody secretion. The data presented in this study directly conflict with such a
schema, and extend previous observations ofmalignant B cell clones (11) and of
the murine system (13-14). Using response to T cell hybridoma-derived BCDFs
as an assay for terminal maturation, we have shown that active proliferation of
B cells actually inhibits B cell differentiation, as measured by antibody secretion.
These data were reproducible using two different B cell proliferation signals
(high-dose SAC or BCPF) and fourdistinct BCDF preparations, so that this effect
did not appear to be due toan unusual combination ofB cell signals. The marked
inhibition ofB cell maturation was not due to a change in the kinetics of BCDF
response as no PFC were detectable even when cultures were assayed up to day
12. Furthermore, addition ofBCDF to cultures up to 96 h after stimulation with
BCPF did not result in any PFC response, suggesting that proliferation signals
were not acting to induce receptors for BCDF. Other considerations such as
depletion of nutrients in the media, cell crowding, and factors secreted from
proliferating B cells were found not to play a significant role in the phenomenon
described (data not shown) .
The finding that active proliferation inhibited response to BCDF led us to
question whether such responses required any proliferation of B cells. Previous
studies using leukemic B cells have suggested that terminal maturation can occur
without proliferation (11), but these cells may have already been beyond the
proliferative stage. In our system, responses to BCDFs MOW 10 and MOPIL
appeared to remain intact in the presence of concentrations ofHU or thymidine
known to inhibit Tand B cell responses to mitogen. In contrast, similar concen-
trations of HU or thymidine abrogated response to two other BCDF prepara-
tions, MTP7 and RAC, as well as the more conventional differentiation signal,
T cells, and PWM. Thus it appears that there are proliferation-independent as
well as -dependent BCDFs, providing further evidence for the heterogeneity of
BCDFs, and suggesting that some BCDFs might act at earlier stages of B cell
maturation. However, since these BCDFs may be acting on already in vivo-
activated B cells that had undergone proliferation, it was necessary to isolate
resting Go B cells characterized by small cell volumes and the absence ofsurface
activation markers 41`2 and Tac (26, 27); this was accomplished by counterflow
elutriation. Addition of BCDF/MOW 10 to isolated resting cells did result in
maturation to antibody-secreting cells. In fact, as might have been predicted
from the earlierdata, moreactivated B cells (with high spontaneousproliferation)
did not respond to this BCDF. Rather, as has been shown by others (23), these
activated Tac+ B cells differentiated in the presence of IL-2. The combination
signal ofSAC (0.001 %) and IL-2 induced differentiation at virtually all stages of
B cell activation, a finding that can be explained by the ability ofSAC to activate
B cells to become Tac+ (25). We and others (8-10) have previously shown that
resting B cells can respond to B cell proliferation signals. Recently other groups
(28-30) have provided evidence that BSF1 is a differentiation factor for resting
cells as well. However, in this context, differentiation was defined as the ability
ofthis factor to induce receptors for proliferation signals or increased expression390
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of class II molecules and not terminal maturation, as we report here. Thus, in
conjunction with the data presented in this study, and previous studies using
malignant B cells or murine splenocytes (11-14), one can state that the resting
B cell has a full complement of receptors for both growth and differentiation
factors. The rationale for such a finding is less clear. Although the major Ig
response with antigen-specific stimulation is directed against the specific antigen,
there is a great deal of nonspecificity inherent in the immune response. Part of
this nonspecificity may be due to the action of polyclonal BCDFs on local B cell
clones, specific and nonspecific. Ifantigen-specific signals are weak, nonspecific
signals may serve to boost the response dramatically. In the presence ofantigen
locally, antigen-specific B cells are more abundant and predominate in the
response. The capability of resting cells to respond to these factors allows for a
more rapid and dramatic response. The finetuning ofaspecific immune response
might come only after several antigenic challenges.
Summary
Using response to four different BCDF preparations as a model of B cell
maturation, we have shown that induction of B cell proliferation abrogates
terminal maturation ofthese cells. In fact, response to some BCDFs can occur in
the presence of inhibitors of DNA replication, suggesting that there are prolif-
eration-independent as well as proliferation-dependent BCDFs. These findings
cannot be explained by changes in the kinetics of the BCDF response, nor can
they be reversed by repletion of media or changing cell densities. Proliferation-
independent BCDFs appear to exert their effects on dense, resting 4172- B cells
rather than more activated B cells. This is in contrast to B cell differentiation
signals of IL-2 alone or SAC and IL-2 in concert. These data suggest that the
current models of B cell activation and maturation may require some reorgani-
zation, relegating the proliferative phase of B cell maturation to a lesser role. In
addition, evidence is provided for the fact that the resting B cell may have the
full complement of receptors for BCDF as well as BCGF and BCPF and may
help account for the inherent nonspecificity of the immune response.
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